Webinar | October 10, 2019

Implementing A Fully Single-Use, Integrated mAb Biosimilars Purification Platform For Next Generation Manufacturing

Source: MilliporeSigma

1000L-scale implementation of fully connected, disposable, advanced DSP platform for next generation mAb production.

Within the biopharmaceutical industry, there is a significant shift toward higher productivity processes resulting in improved economics without compromising robustness. Therefore, integrated continuous production technologies are of greatest interest. 

Next Generation Biopharmaceutical Downstream Process is a European-funded collaborative project that aims at implementing a fully integrated manufacturing platform for biosimilar mAb based on continuous chromatography, in combination with single-use disposable technologies for all unit operations of DSP on pilot/small production scale together with incorporation of advanced analytical tools.